A phase I clinical study of inhaled nitric oxide in healthy adults

Slides:

Advertisements

Similar presentations

Pulmonary Function Tests (PFTs)

Advertisements

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pulmonary function in primary pulmonary hypertension.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Efficacy of Inhalational Nitric Oxide Therapy in the Clinical Management of Persistent Pulmonary Hypertension of the Newborn John P. Kinsella, M.D.,

Pulmonary response in sarcoidosis

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Inhaled nitric oxide reduces human lung allograft dysfunction

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

Christopher C. Miller, Christopher A

The immediate effect of musculoskeletal physiotherapy techniques and massage on pain and ease of breathing in adults with cystic fibrosis Annemarie Lee,

IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection Hannah K. Bayes, Neil D. Ritchie, Christopher Ward,

Distinct endotypes of steroid-resistant asthma characterized by IL-17Ahigh and IFN- γhigh immunophenotypes: Potential benefits of calcitriol Emma S. Chambers,

A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis Emer P. Reeves, David A. Bergin, Sean Fitzgerald, Elaine.

William G. Flight, Jonathan Shaw, Susan Johnson, A

Inhaled antibiotic therapy: What drug. What dose. What regimen

Mortality Risk and Pulmonary Function in Adults With Cystic Fibrosis at Time of Wait Listing for Lung Transplantation Don Hayes, MD, MS, Stephen Kirkby,

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation Gemma L. Zeybel, Jeffrey P. Pearson, Amaran Krishnan,

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months Arturo Navarro-Martin, MD, Samantha Aso, MD, Jon Cacicedo,

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M

Lung Function after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Longitudinal Study in a Population-Based Cohort Hilde Hylland Uhlving,

Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model K. Thomsen, L. Christophersen, T. Bjarnsholt, P.Ø.

The ease of breathing test tracks clinical changes in cystic fibrosis

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Controlled clinical trials in cystic fibrosis — are we doing better?

Regional Emphysema Score Predicting Overall Survival, Quality of Life, and Pulmonary Function Recovery in Early-Stage Lung Cancer Patients Jie Dai, PhD,

Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis Diana Bilton, Gabriel Bellon, Brett Charlton, Peter Cooper,

Volume 154, Issue 5, Pages (November 2018)

Effects of Extended Pleurectomy and Decortication on Quality of Life and Pulmonary Function in Patients With Malignant Pleural Mesothelioma David Burkholder,

Supreme laryngeal mask airway for laparoscopic cholecystectomy in patient with severe pulmonary fibrosis M. Carron, A. Marchet, C. Ori British Journal.

Treatment response of airway clearance assessed by single-breath washout in children with cystic fibrosis Chiara Abbas, Florian Singer, Sophie Yammine,

Pulmonary nocardiosis in cystic fibrosis

Physiologic endpoints for clinical studies for cystic fibrosis

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Valerie Waters, Eshetu G

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Cytokine gene polymorphisms and severity of CF lung disease

تست عملکرد ریوی SPIROMETERY.

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Mark F. Berry, MD, Chi-Fu Jeffrey.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Gautham Marigowda, Fang Liu, David Waltz Journal of Cystic Fibrosis

Ribavirin in Desquamative Interstitial Pneumonia

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate.

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Predictors of non-referral of patients with cystic fibrosisfor lung transplant evaluation in the United States Kathleen J. Ramos, Bradley S. Quon, Kevin.

Airway inflammation in mild cystic fibrosis

Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation Noa Nezer M. Sc, David Shoseyov, Eitan.

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Analgesia and pulmonary function after lung surgery: is a single intercostal nerve block plus patient-controlled intravenous morphine as effective as.

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Is pulmonary function damaged by neoadjuvant lung cancer therapy

Journal of Cystic Fibrosis

Presentation transcript:

A phase I clinical study of inhaled nitric oxide in healthy adults Chris Miller, Minna Miller, Bevin McMullin, Gilly Regev, Lena Serghides, Kevin Kain, Jeremy Road, Yossef Av-Gay Journal of Cystic Fibrosis Volume 11, Issue 4, Pages 324-331 (July 2012) DOI: 10.1016/j.jcf.2012.01.003 Copyright © 2012 Terms and Conditions

Fig. 1 Methemoglobin levels (%) before, during and after inhalation of 160ppm nitric oxide in healthy human individuals. The 10 individuals performed 5 NO treatment courses daily, lasting 30min each, for 5 consecutive days. Methemoglobin levels were measured using a pulse oximeter. A, Values represent pooled values of 250 individual 30min NO treatment courses from 10 subjects and pooled values obtained at 120min, 180min and 240min after NO treatment was discontinued. B, Values represent pooled values of 10 individuals at the beginning and end of 30min NO treatment courses and pooled values obtained 8, 12 and 26days after NO treatment was discontinued. Journal of Cystic Fibrosis 2012 11, 324-331DOI: (10.1016/j.jcf.2012.01.003) Copyright © 2012 Terms and Conditions

Fig. 2 Pulmonary function before, during and after inhalation of 160ppm nitric oxide in healthy human individuals. Baseline values of pulmonary function tests were obtained within 7days prior to NO therapy. Values during NO treatment were obtained on day 2. Further values were determined after the final NO treatment on day 5 and on days 8, 12 and 26. FEV1: forced expiratory volume in 1 second; MMEF: maximum mid-expiratory flow; DLCO: carbon monoxide diffusing capacity; FVC: forced vital capacity TLC: total lung capacity; RV: residual volume. Data are presented as means of all ten subjects and absolute differences compared to baseline prior to NO treatment. Statistical differences were assessed by Mann–Whitney test. Journal of Cystic Fibrosis 2012 11, 324-331DOI: (10.1016/j.jcf.2012.01.003) Copyright © 2012 Terms and Conditions

Fig. 3 Cytokine blood levels before and after inhalation of 160ppm nitric oxide in healthy human individuals. Blood was collected within 7days prior to NO therapy. Further blood samples were taken each day during NO treatment and on days 8, 12 and 26. Plasma levels of tumour necrosis factor (TNF)α, interleukin (IL)-1ß, IL-6, IL-8, IL-10 and IL-12p70 were determined by a cytometric bead array. Statistical differences were compared by repeated measures ANOVA with Bonferroni post test for parametric data (IL-6, IL-8, IL-10, IL-12p70), or Friedman test with Dunn's post test for non-parametric data (TNF and IL-1b). Journal of Cystic Fibrosis 2012 11, 324-331DOI: (10.1016/j.jcf.2012.01.003) Copyright © 2012 Terms and Conditions

Fig. 4 Plasma levels of angiopoietin (Ang)-1 and Ang-2 before and after inhalation of 160ppm nitric oxide in healthy human individuals. Blood was collected within 7days prior to NO therapy. Further blood samples were taken each day during NO treatment and on days 8, 12 and 26. Plasma levels of Ang-1, Ang-2, and Ang-2/Ang-1 ratios were determined using a cytometric bead array. Statistical differences were assessed compared by Friedman test with Dunn's post test. Journal of Cystic Fibrosis 2012 11, 324-331DOI: (10.1016/j.jcf.2012.01.003) Copyright © 2012 Terms and Conditions